Search Results 631-640 of 18943 for creatine

1. A Study to Test Nivolumab with Usual Chemotherapy Treatment or Usual Chemotherapy Treatment Alone to Treat Recurrent or Metastatic Nasopharyngeal Cancer - Mayo Clinic

   Serum creatinine ≤ 1.5 x ULN OR calculated creatinine clearance (CrCl) ... creatinine levels > 1.5 x ULN. In this protocol, cisplatin or carboplatin ...

2. Mechanisms of Anabolic Resistance in Older Humans - Mayo Clinic

   Renal failure (serum creatinine > 1.5mg/dl); Chronic active liver disease (AST > 144IU/L or ALT > 165IU/L); Oral warfarin group medications or history of ...

3. Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance ≥ 40 mL ... For subjects with UC: ≤ 2 mg/mg (≤ 226.4 mg/mmol) creatinine. Capable ...

4. Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery - Mayo Clinic

   Serum creatinine ≤ 1.5 X institutional upper limit of normal OR creatinine clearance ≥ 60 mL/min/1.73 m^2 for patients with creatinine levels above ...

5. A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) - Mayo Clinic

   Creatinine < 1.5 times normal OR creatinine clearance ≥ 60 mL/min. Toxicity from prior therapies recovered to Grade ≤ 1 or subject's baseline, except for ...

6. Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas - Mayo Clinic

   Renal. Serum creatinine or measured or calculated creatinine clearance (CrCL)** ≤ 1.5 × upper limit of normal (ULN) or CrCL ≥ 30 mL/min for patients with a ...

7. Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. - Mayo Clinic

   Serum creatinine within normal limits or calculated creatinine clearance >60 mL/min/1.73 m2 using the Cockroft-Gault method (Appendix 2) for participants ...

8. A Study Of ATR-101 For The Treatment Of Cushing’s Syndrome - Mayo Clinic

   Serum creatinine > 1.5 × ULN; Creatinine clearance < 60 mL/min. Pregnant, breast-feeding, has conceived within the 6 months prior to screening, or intends to ...

9. Phase I Study Of BL0020, A Novel Anti-tumor Drug, In Adult Subjects With Advanced Solid Tumors - Mayo Clinic

   * Creatinine \> 1.5×ULN or creatinine clearance \< 50 mL/min. 16. Those who are known to be allergic to the active ingredient or excipients of the ...

10. Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis - Mayo Clinic

    Serum creatinine ≥ 2.0 mg/dL or estimated creatinine clearance < 60 mL/min (using the Cockcroft-Gault equation);; Serum aspartate aminotransferase (AST) or ...